NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Intellia Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$11.58+0.16 (+1.40%)

Close on Oct 19, 2026

Market cap: $1.55B
P/E (TTM): –
Dividend yield: –

Intellia Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	68	58	36	52	33	58	43	30	26	16	–
Cost of Revenue	–	–	–	–	0	0	0	0	–	–	–
Gross Profit	–	–	–	–	33	58	43	30	–	–	–
Research & Development	389	466	435	420	230	150	108	89	68	32	11
General & Administrative	120	126	116	90	71	44	41	32	28	17	8.28
Total Costs & Expenses	509	592	552	510	301	195	149	121	96	49	19
Operating Income	-441	-534	-515	-458	-268	-137	-106	-91	-70	-32	-13
Interest & Investment Income	29	48	50	8.54	1.28	2.35	6.84	5.53	2.01	0.53	–
Income from Equity Investments	0	0	-16	-11	-1.33	0	0	–	–	–	–
Other Non-Operating Income	28	15	34	-16	-0.04	2.35	6.84	–	–	–	–
Gain (Loss) on Investments	0	-33	0	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	-0.53	0.08	-0.07	0.16	0	-0.04	0.00	-0.08	-0.17	-0.01	-0.01
Pretax Income	–	–	–	–	–	–	–	–	-68	-32	-13
Income Tax Expense	0	–	–	–	–	–	–	–	–	0	-1.01
Net Income incl. Noncontrolling Interests	-413	-519	-481	-474	-268	-134	-100	-85	-68	-32	–
Net Income	-413	-519	-481	-474	-268	-134	-474	-85	-68	-32	-12
EPS (Basic)(per share)	-3.81	-5.25	-5.42	-6.16	-3.78	-2.40	-2.11	-1.98	-1.88	-1.42	-51.02
EPS (Diluted)(per share)	-3.81	-5.25	-5.42	-6.16	-3.78	-2.40	-2.11	-1.98	-1.88	-1.42	-51.02
Shares Outstanding (Basic, Weighted)(shares)	108	99	89	77	71	56	0.05	43	36	22	0.24
Shares Outstanding (Diluted, Weighted)(shares)	108	99	89	77	71	56	0.05	43	36	22	0.24
EBITDA	-431	-524	-506	-451	-261	-130	-101	-86	-67	-31	-13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -711.7%
Net margin: -672.2%
Return on equity, FY2025: -53.5%

Financial strength

Current ratio: 6.65
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 133.7%

Valuation

P/E ratio: –
Price to sales: 25.98
Price to book: 2.12
Dividend yield: –